PAREXEL TO UNVEIL EXPERTISE THAT MAKES THE DIFFERENCE? TAGLINE AT BIO AND DIA
BOSTON, MA, June 20, 2005 — PAREXEL International Corporation (Nasdaq: PRXL), a leading global bio/pharmaceutical services provider, will unveil its new tagline Expertise that makes the Difference™ at the upcoming BIO and DIA industry meetings, to be held respectively June 19-22 in Philadelphia and June 26-29 in Washington, D.C. PAREXEL is retiring its former tagline Clinically Thinking to adopt the new tagline Expertise that makes the Difference™ as part of an effort to educate the industry that PAREXEL is more than a clinical research organization (CRO). The Company provides an expansive base of expertise, services, and advanced technologies across the drug development continuum, from Proof-of-Concept through commercialization.
“PAREXEL is helping both small and large bio/pharmaceutical companies to navigate increasing regulatory, scientific, and business challenges and successfully bring new products to market,” said Josef von Rickenbach, Chairman and CEO, PAREXEL. “Due to the extensive portfolio of services and advanced technologies PAREXEL has built over time in response to client needs, we believe we are in a position to meet the diverse needs of the industry.”
“Our new tagline Expertise that makes the Difference™ accentuates the core benefits we deliver to clients,” said von Rickenbach. “Our expertise makes positive, measurable differences so that clients can achieve unparalleled business performance,” said von Rickenbach.
“We not only have a comprehensive toolkit of services, but we also know what tools to apply at which points during the various phases of strategy, development, and commercialization to help our clients achieve higher productivity levels in a shorter timeframe with improved returns on investment,” said Susan Murphy Warren, Vice President of Corporate Marketing and Strategy, PAREXEL. “Additionally, we can integrate the appropriate technologies into our clients’ programs to enhance effectiveness and accelerate decisions and processes associated with the development and launch of new products.”
The introduction of the new tagline is aligned with the latest evolution of PAREXEL’s efforts to meet clients’ needs. For more than 20 years PAREXEL’s capabilities have evolved with client demand. PAREXEL was established in 1983 as a regulatory affairs company, helping clients navigate FDA filings. Following several strategic acquisitions during the late 1980s into the 1990s, PAREXEL built up its core business as a clinical research organization, providing expertise in areas including biostatistics, data management, site recruitment and monitoring. Over the past decade, the Company has expanded its service offering beyond clinical research to provide consulting for the planning of regulatory and commercialization strategies and process development and optimization. PAREXEL also expanded its offerings to provide pre- and post-launch medical marketing services. Continuing to respond to customer-driven requests, PAREXEL started offering technology-driven solutions in 1998 and formed its technology subsidiary Perceptive Informatics™ in 2000. In recent years, PAREXEL has helped companies address productivity challenges through its organizational effectiveness consulting practice. The Company has also helped clients build strategic marketing considerations earlier into the drug development cycle.
Expertise across the Entire Product Lifecycle
Both large and small companies turn to PAREXEL to take advantage of the Company’s global presence, deep therapeutic area experience, and capabilities and expertise across the entire product lifecycle. Small, emerging bio/pharmaceutical companies work with PAREXEL for the full spectrum of the Company’s expertise while large pharmaceutical companies frequently utilize PAREXEL to expand their capacity and supplement in-house expertise.
PAREXEL services include:
- Drug development planning
- Process design and optimization
- Regulatory and strategic marketing planning
- Early Phase Development
- Investigational New Drug (IND) filings
- Late Phase Development
- Comprehensive activities for Phase I-III, including medical, patient recruitment and retention, site recruitment and management, project management, monitoring, biostatistics, data management and others
- Peri-approval/Phase IV clinical
- Health outcomes/reimbursement
- Patient assistance programs
- Continuing Medical Education (CME) and training
- Market development
Advanced Technologies through Perceptive Informatics™, a PAREXEL Company, include:
- CTMS (Clinical Trial Management Systems)
- IVRS (Interactive Voice Response Systems)
- Medical Imaging
PAREXEL International Corporation, a leading global bio/pharmaceutical service provider, offers a broad range of consulting, clinical research and medical marketing services to the worldwide pharmaceutical, biotechnology and medical device industries. PAREXEL® also provides advanced information technology through its subsidiary, Perceptive Informatics™, a PAREXEL Company. Headquartered near Boston, MA, PAREXEL currently operates in 53 locations throughout 37 countries around the world, and has approximately 5,070 employees.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.